home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Seagen Inc. - Common Stock (NQ:SGEN)

N/A UNCHANGED

Last Price Updated: 4:00 PM EST, Dec 13, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Seagen Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

17 18 Next >

JMP Securities Maintains Market Outperform Rating for Seagen: Here's What You Need To Know ↗

February 17, 2023

Via Benzinga

Why Boston Beer Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

February 16, 2023

Gainers TravelCenters of America Inc. (NASDAQ: TA) shares jumped 70.5% to $84.32 after BP announced it will acquire the company for $86 per share in cash.

Via Benzinga

Why Seagen Stock Is Soaring Today ↗

February 16, 2023

Investors and analysts liked what they heard in the company's Q4 update.

Via The Motley Fool

Seagen (SGEN) Q4 2022 Earnings Call Transcript ↗

February 15, 2023

SGEN earnings call for the period ending December 31, 2022.

Via The Motley Fool

8 Analysts Have This to Say About Seagen ↗

February 13, 2023

Via Benzinga

Analyst Ratings for Seagen ↗

January 20, 2023

Via Benzinga

Analysts Are Bullish On Seagen's Catalyst-Rich Pipeline, Finding No Problem With No M&A ↗

February 16, 2023

Via Benzinga

KBR, Twilio, Roku And Other Big Stocks Moving Higher On Thursday ↗

February 16, 2023

U.S. stocks traded lower, with the Dow Jones dropping over 250 points on Thursday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Seattle Genetics' 'Refreshing' Enthusiasm Drives Stock Surge; Alkermes Briefly Breaks Out ↗

February 16, 2023

Seattle Genetics' guidance deliberately excludes a looming opportunity for Padcev.

Via Investor's Business Daily

Pagaya Technologies To Rally Around Over 120%? Here Are 10 Other Analyst Forecasts For Thursday ↗

February 16, 2023

Keybanc boosted the price target for Twilio Inc. (NYSE: TWLO) from $77 to $89. Keybanc analyst Thomas Blakey maintained an Overweight rating on the stock. Twilio shares gained 6.4% to close at $66.05...

Via Benzinga

Seagen Reports Fourth Quarter and Full Year 2022 Financial Results

February 15, 2023

From Seagen Inc.

Via Business Wire

2 Under-the-Radar Biotech Stocks to Buy in 2023 ↗

February 14, 2023

These stocks may soon start turning heads with their revenue growth.

Via The Motley Fool

Seagen to Highlight Research in Urothelial Cancer at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium

February 13, 2023

From Seagen Inc.

Via Business Wire

RH To Rally Over 15%? Here Are 10 Other Analyst Forecasts For Monday ↗

February 06, 2023

Citigroup boosted the price target for RH (NYSE: RH) from $305 to $380. Citigroup analyst Steven Zaccone maintained a Buy rating. Hershey shares fell 4% to $330.00 in pre-market trading.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 6, 2023 ↗

February 06, 2023

Via Benzinga

February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More ↗

January 31, 2023

The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new...

Via Benzinga

Union Pacific To Rally Over 11%? Here Are 10 Other Analyst Forecasts For Wednesday ↗

January 25, 2023

Keybanc raised the price target for Reliance Steel & Aluminum Co. (NYSE: RS) from $225 to $235. Keybanc analyst Philip Gibbs maintained an Overweight rating. Reliance Steel shares fell 0.2% to close at...

Via Benzinga

Seagen's Tukysa Becomes First FDA-Approved Treatment For HER2-Positive Metastatic Colorectal Cancer ↗

January 20, 2023

Via Benzinga

Seagen Announces FDA Accelerated Approval of TUKYSA® (tucatinib) in Combination with Trastuzumab for People with Previously Treated RAS Wild-Type, HER2-Positive Metastatic Colorectal Cancer

January 19, 2023

From Seagen Inc.

Via Business Wire

Seagen to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2022 Financial Results on February 15, 2023

January 19, 2023

From Seagen Inc.

Via Business Wire

Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors ↗

December 27, 2022

Biopharma stocks were not immune to the broader market downturn seen for much of 2022.

Via Benzinga

Have A Look At William Blair's Top Biotech Picks For 2023 ↗

December 25, 2022

William Blair & Company's report outlined some key themes and significant trends to monitor while entering 2023, providing its top stock ideas for the upcoming 12-month period.

Via Benzinga

Seagen to Present at the J.P. Morgan Healthcare Conference

December 20, 2022

From Seagen Inc.

Via Business Wire

Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer

December 20, 2022

From Seagen Inc.

Via Business Wire

Why Seagen Stock Is Trading Higher During Monday's Session ↗

December 12, 2022

Seagen Inc (NASDAQ: SGEN) shares are trading higher by 4.79% to $129.94 by after the company announced results from the Phase 2 clinical trial of ADCETRIS with novel immunotherapy combination in...

Via Benzinga

Seagen Announces Results from Phase 2 Clinical Trial of ADCETRIS® (brentuximab vedotin) with Novel Immunotherapy Combination in Patients with Advanced- and Early-Stage Classical Hodgkin Lymphoma

December 12, 2022

From Seagen Inc.

Via Business Wire

2 Growth Stocks to Buy if the Bear Market Continues in 2023 ↗

December 01, 2022

These stocks aren't bargain buys just yet, but they could be soon.

Via The Motley Fool

Research and Development of Advanced Therapeutics for Ovarian Cancer Fueling Hope

December 01, 2022

EQNX::TICKER_START (OTCQB:BVAXF),(NASDAQ:CTIC),(NASDAQ:SGEN),(NYSE:MRK),(NASDAQ:IMGN) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Intellectual Property

Seagen to Highlight ADCETRIS® (brentuximab vedotin) Clinical Progress at the 2022 American Society of Hematology (ASH) Annual Meeting

December 01, 2022

From Seagen Inc.

Via Business Wire

Imago BioSciences Catapults To Record High On Merck's $1.35 Billion Buyout ↗

November 21, 2022

Seagen who? Merck is putting its cash to work buying a smaller biotech company.

Via Investor's Business Daily

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com